JP2009525323A - 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法 - Google Patents

神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法 Download PDF

Info

Publication number
JP2009525323A
JP2009525323A JP2008553193A JP2008553193A JP2009525323A JP 2009525323 A JP2009525323 A JP 2009525323A JP 2008553193 A JP2008553193 A JP 2008553193A JP 2008553193 A JP2008553193 A JP 2008553193A JP 2009525323 A JP2009525323 A JP 2009525323A
Authority
JP
Japan
Prior art keywords
stathmin
tlr3
amino acid
cells
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008553193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525323A5 (enExample
Inventor
ノート，ヨハネス，マリア ファン
ブシブシ，マリカ
Original Assignee
ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー filed Critical ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー
Publication of JP2009525323A publication Critical patent/JP2009525323A/ja
Publication of JP2009525323A5 publication Critical patent/JP2009525323A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008553193A 2006-02-03 2007-02-02 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法 Pending JP2009525323A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06075265A EP1815863A1 (en) 2006-02-03 2006-02-03 Use of TLR3 agonists for the treatment of neurodegenerative disorders
PCT/NL2007/050045 WO2007089151A1 (en) 2006-02-03 2007-02-02 Use of tlr3 agonists for the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2009525323A true JP2009525323A (ja) 2009-07-09
JP2009525323A5 JP2009525323A5 (enExample) 2010-03-25

Family

ID=36087734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008553193A Pending JP2009525323A (ja) 2006-02-03 2007-02-02 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法

Country Status (5)

Country Link
US (1) US20090253622A1 (enExample)
EP (2) EP1815863A1 (enExample)
JP (1) JP2009525323A (enExample)
AU (1) AU2007210379A1 (enExample)
WO (1) WO2007089151A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524402A (ja) * 2012-07-19 2015-08-24 ジム トレード コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー リージンク コマンディトゲゼルシャフト 創傷治療用の薬剤

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130425A1 (en) * 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
WO2008083351A2 (en) 2006-12-29 2008-07-10 Genifuel Corporation Controlled growth environments for algae cultivation
GB201022049D0 (en) * 2010-12-29 2011-02-02 Imp Innovations Ltd Methods
WO2015108595A1 (en) 2014-01-15 2015-07-23 Nikolai Khodarev Anti-tumor therapy
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
EP3298131B1 (en) 2015-05-20 2023-04-26 The Regents of The University of California Method for generating human dendritic cells for immunotherapy
CA3003145C (en) 2015-10-30 2025-11-18 The Regents Of The University Of California METHODS FOR GENERATION OF T LYMPHOCYTES FROM STEM CELLS AND IMMUNOTHERAPY METHODS USING SAID T LYMPHOCYTES
EP3318270A1 (en) * 2016-11-08 2018-05-09 RMB-Research GmbH Stathmin composition and method for treating wounds
EP3538668B8 (en) 2016-11-10 2025-04-23 Talis Biomedical Corporation Polynucleotides for the amplification and detection of chlamydia trachomatis
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
US10450616B1 (en) 2018-05-09 2019-10-22 Talis Biomedical Corporation Polynucleotides for the amplification and detection of Chlamydia trachomatis
US12496327B2 (en) 2019-01-14 2025-12-16 President And Fellows Of Harvard College Methods and compositions for restoring STMN2 levels
US11969402B2 (en) 2019-05-16 2024-04-30 The Johns Hopkins University Compositions and methods for skin rejuvenation
US20220333105A1 (en) * 2019-06-03 2022-10-20 Quralis Corporation Oligonucleotides and methods of use for treating neurological diseases
WO2021076964A1 (en) * 2019-10-17 2021-04-22 Icahn School Of Medicine At Mount Sinai Stathmin 2 (stmn2) as a therapeutic target for parkinson's disease
US11891662B2 (en) * 2019-12-02 2024-02-06 Talis Biomedical Corporation Polynucleotides for amplification and detection of human beta actin
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US11047007B1 (en) 2020-03-23 2021-06-29 Talis Biomedical Corporation Polynucleotides for amplification and detection of SARS-CoV-2
WO2022003598A1 (en) 2020-07-02 2022-01-06 Viiv Healthcare Company Method of achieving hiv viral remission using long-acting antiretroviral agents
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
WO2004078925A2 (en) * 2003-02-28 2004-09-16 Irm Llc Methods and compositions for treating and preventing neurodegenerative diseases
WO2005106038A2 (en) * 2004-04-15 2005-11-10 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044935A1 (en) * 1997-06-11 2003-03-06 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
EP1242443A4 (en) * 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
AU2002220131A1 (en) * 2000-12-01 2002-06-11 Board Of Trustees Of The University Of Arkansas Compositions, methods, apparatus and products comprising a stathmin/oncoprotein 18 sequence for detecting and treating cancer
AU2003302386B2 (en) * 2002-11-26 2010-04-01 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
WO2004078925A2 (en) * 2003-02-28 2004-09-16 Irm Llc Methods and compositions for treating and preventing neurodegenerative diseases
WO2005106038A2 (en) * 2004-04-15 2005-11-10 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6012029348; 日本神経精神薬理学雑誌 Ｖｏｌ．１７, 1997, ｐ．１５９-１６７ *
JPN6012029351; Ｊｏｕｒｎａｌ　ｏｆ　Ｎｕｅｒｏｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１５９, 2005, ｐ．１２-１９ *
JPN6012029353; Ｎｅｕｒｏｂｉｏｌｏｇｙ　ｏｆ　Ａｇｉｎｇ Ｖｏｌ．１７，　Ｎｏ．３, 1996, ｐ．３３１-３４１ *
JPN6012029355; Ｎｅｕｒｏｂｉｏｌｏｇｙ　ｏｆ　Ａｇｉｎｇ Ｖｏｌ．１６，　Ｎｏ．６, 1995, ｐ．８８３-８９４ *
JPN6012029357; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒｏｓｃｉｅｎｃｅ Ｖｏｌ．２５，　Ｎｏ．３, 2005, ｐ．７３７-７４７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524402A (ja) * 2012-07-19 2015-08-24 ジム トレード コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー リージンク コマンディトゲゼルシャフト 創傷治療用の薬剤

Also Published As

Publication number Publication date
WO2007089151A1 (en) 2007-08-09
EP1815863A1 (en) 2007-08-08
AU2007210379A1 (en) 2007-08-09
US20090253622A1 (en) 2009-10-08
EP1991251A1 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
JP2009525323A (ja) 神経変性疾患の処置の為にｔｌｒ３アゴニストを使用する方法
JP2023082115A (ja) 老化関連症状を治療する方法および医薬組成物
CN104981479B (zh) 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病
Sarver et al. FAM19A (TAFA): An emerging family of neurokines with diverse functions in the central and peripheral nervous system
da Rocha et al. APP binds to the EGFR ligands HB-EGF and EGF, acting synergistically with EGF to promote ERK signaling and neuritogenesis
CN112703008A (zh) 治疗癫痫、发作和cns疾病的经口抗炎肽
CN106905427B (zh) 用于抑制炎症的肽
JP2020518261A (ja) Ｃ末端ｃｄｎｆ断片及びｃ末端ｍａｎｆ断片、それらを含む医薬組成物、並びにそれらの使用
CN101534648B (zh) 使用mntf肽及其类似物治疗神经紊乱的方法
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
US20040002460A1 (en) Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom
US7572450B2 (en) Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteins
US7514407B2 (en) Spheron component peptides and pharmaceutical compositions
US20090233854A1 (en) Novel application of apelin
US10738095B2 (en) Engineered CCL20 locked dimer polypeptide
US11571462B2 (en) Engineered CCL20 locked dimer polypeptide
WO2025168038A1 (en) Methods and compositions for ameliorating impairment of regenerative and cognitive function
JP2002509693A (ja) カドヘリン由来成長因子及びその使用
EP3743434A1 (en) Cationic peptides with immunomodulatory and/or anti-biofilm activities
JP4760377B2 (ja) ＧＰＲ１０３−ｌｉｋｅ受容体蛋白質に対するリガンドの新規用途
US20230390359A1 (en) Use of reelin for treating cardiac diseases
EP1541166B1 (en) Preventing cell death using segments of neural thread proteins
Minkiewicz ATP activation of the NLRP2 inflammasome in human astrocytes
CN121337952A (zh) 用于抑制炎症的肽
HK1216318B (en) Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121107